EP1545596A4 - Use of histamine h4 receptor modulators for the treatment of allergy and asthma - Google Patents
Use of histamine h4 receptor modulators for the treatment of allergy and asthmaInfo
- Publication number
- EP1545596A4 EP1545596A4 EP03794649A EP03794649A EP1545596A4 EP 1545596 A4 EP1545596 A4 EP 1545596A4 EP 03794649 A EP03794649 A EP 03794649A EP 03794649 A EP03794649 A EP 03794649A EP 1545596 A4 EP1545596 A4 EP 1545596A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- histamine
- allergy
- asthma
- treatment
- receptor modulators
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40873602P | 2002-09-06 | 2002-09-06 | |
US408736P | 2002-09-06 | ||
PCT/US2003/027943 WO2004021999A2 (en) | 2002-09-06 | 2003-09-05 | Use of histamine h4 receptor modulators for the treatment of allergy and asthma |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1545596A2 EP1545596A2 (en) | 2005-06-29 |
EP1545596A4 true EP1545596A4 (en) | 2005-12-28 |
Family
ID=31978667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03794649A Withdrawn EP1545596A4 (en) | 2002-09-06 | 2003-09-05 | Use of histamine h4 receptor modulators for the treatment of allergy and asthma |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1545596A4 (en) |
JP (1) | JP2006510590A (en) |
AU (1) | AU2003265961A1 (en) |
CA (1) | CA2497788A1 (en) |
MX (1) | MXPA05002577A (en) |
WO (1) | WO2004021999A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2587141A1 (en) * | 2004-11-24 | 2006-06-01 | Pfizer Inc. | Octahydropyrrolo[3,4-c]pyrrole derivatives |
EP1671972A1 (en) * | 2004-11-24 | 2006-06-21 | Pfizer Limited | Octahydropyrrolo[3,4-c]pyrrole derivatives |
WO2007117465A2 (en) | 2006-03-31 | 2007-10-18 | Abbott Laboratories | Indazole compounds |
EP2298772A1 (en) * | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
KR100954138B1 (en) * | 2007-12-31 | 2010-04-20 | 부산대학교 산학협력단 | An agent comprising adipose tissue?derived stem cells as effective ingredient for prevention and treatment of allergic rhinitis or asthma |
EP2201982A1 (en) * | 2008-12-24 | 2010-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Histamine H4 receptor antagonists for the treatment of vestibular disorders |
JP2012102017A (en) * | 2009-03-03 | 2012-05-31 | Astellas Pharma Inc | Indole compound |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072548A2 (en) * | 2001-03-09 | 2002-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic compounds and their use as histamine h4 ligands. |
WO2003057919A2 (en) * | 2001-12-21 | 2003-07-17 | Ortho-Mcneil Pharmaceutical, Inc. | The use of histamine h4 receptor antagonist for the treatment of inflammatory response |
WO2004022061A1 (en) * | 2002-09-06 | 2004-03-18 | Janssen Pharmaceutica, N.V. | Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis |
WO2004022060A2 (en) * | 2002-09-06 | 2004-03-18 | Janssen Pharmaceutica, N.V. | (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001259513A1 (en) * | 2000-05-05 | 2001-11-20 | Wyeth | Human histamine h4 receptor |
NZ523157A (en) * | 2000-05-31 | 2004-08-27 | Ortho Mcneil Pharm Inc | DNAs encoding mammalian histamine receptor of the H4 subtype |
GB0101223D0 (en) * | 2001-01-17 | 2001-02-28 | Pfizer Ltd | Histamine receptor antagonists |
-
2003
- 2003-09-05 EP EP03794649A patent/EP1545596A4/en not_active Withdrawn
- 2003-09-05 MX MXPA05002577A patent/MXPA05002577A/en not_active Application Discontinuation
- 2003-09-05 CA CA002497788A patent/CA2497788A1/en not_active Abandoned
- 2003-09-05 JP JP2004534688A patent/JP2006510590A/en not_active Withdrawn
- 2003-09-05 AU AU2003265961A patent/AU2003265961A1/en not_active Abandoned
- 2003-09-05 WO PCT/US2003/027943 patent/WO2004021999A2/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072548A2 (en) * | 2001-03-09 | 2002-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic compounds and their use as histamine h4 ligands. |
WO2003057919A2 (en) * | 2001-12-21 | 2003-07-17 | Ortho-Mcneil Pharmaceutical, Inc. | The use of histamine h4 receptor antagonist for the treatment of inflammatory response |
WO2004022061A1 (en) * | 2002-09-06 | 2004-03-18 | Janssen Pharmaceutica, N.V. | Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis |
WO2004022060A2 (en) * | 2002-09-06 | 2004-03-18 | Janssen Pharmaceutica, N.V. | (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders |
Non-Patent Citations (4)
Title |
---|
HOFSTRA C L ET AL: "Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 305, no. 3, June 2003 (2003-06-01), pages 1212 - 1221, XP002352480, ISSN: 0022-3565 * |
LIU C ET AL: "Comparison of human, mouse, rat and guinea pig histamine H4 receptors reveals substantial pharmacological species variation", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 299, no. 1, 2001, pages 121 - 130, XP009013631, ISSN: 0022-3565 * |
O'REILLY M ET AL: "Identification of a histamine H4 receptor of human eosinophils - role in eosinophil chemotaxis", JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH, MARCEL DEKKER, NEW YORK, NY, US, vol. 22, no. 1-4, February 2002 (2002-02-01), pages 431 - 448, XP009047851, ISSN: 1079-9893 * |
THURMOND R L ET AL: "A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 309, no. 1, 1 April 2004 (2004-04-01), pages 404 - 413, XP002352481, ISSN: 0022-3565 * |
Also Published As
Publication number | Publication date |
---|---|
JP2006510590A (en) | 2006-03-30 |
WO2004021999A2 (en) | 2004-03-18 |
AU2003265961A1 (en) | 2004-03-29 |
WO2004021999A3 (en) | 2004-10-07 |
EP1545596A2 (en) | 2005-06-29 |
MXPA05002577A (en) | 2005-09-20 |
CA2497788A1 (en) | 2004-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1205748A1 (en) | Therapeutic epitopes and uses thereof | |
AU2003256253A8 (en) | Aerosol for medical treatment and methods | |
EP1509279A4 (en) | Device and method for the treatment of cardiac disorders | |
HK1079203A1 (en) | Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders | |
EP1576033A4 (en) | Process for producing polysiloxanes and use of the same | |
IL164703A0 (en) | ImidazoÄ1,2-AÜpyrazin-8-ylamines method of making and method of use thereof | |
AU2003281736A8 (en) | Electrodes and related devices | |
AU2003259717A8 (en) | Modulators of rabggt and methods of use thereof | |
HK1203216A1 (en) | Materials and methods for treating disorders of the ear | |
HUP0401808A3 (en) | Dosage forms, devices and methods of treatment | |
GB2389410B (en) | Lighter and method of use | |
EP1476150A4 (en) | Carboxyfullerenes and methods of use thereof | |
AU2003286737A8 (en) | Apparatuses and methods for the manufacture and placement of truss assemblies | |
GB2390978B (en) | Applicator and/or stimulator device | |
EP1545507A4 (en) | Activated checkpoint therapy and methods of use thereof | |
EP1518925A4 (en) | Crystal of glucokinase protein, and method for drug design using the crystal | |
EP1545596A4 (en) | Use of histamine h4 receptor modulators for the treatment of allergy and asthma | |
GB0207410D0 (en) | Compounds and their therapeutic use | |
AU2001249262A1 (en) | Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof | |
AU2003262229A1 (en) | Preventive and/or therapeutic drugs for asthma | |
AU2003250831A1 (en) | Use of hec1 antagonists in the treatment of proliferative disorders and cancer | |
AU2003223094A1 (en) | Hand held device for inhalation therapy and method of use thereof | |
AU2003259689A1 (en) | 3-imino-2-indolones for the treatment of depression and/or anxiety | |
GB0207409D0 (en) | Benzofuran-2H-3-one compounds and their therapeutic use | |
IL142102A0 (en) | Zinc-sensing receptor and methods of treatment of disorders associated herewith |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050405 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20051115 |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7G 01N 33/53 B Ipc: 7C 07K 16/00 B Ipc: 7A 61K 47/00 B Ipc: 7A 61K 39/00 A |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: THURMOND, ROBIN, L. Inventor name: LING, PING Inventor name: LEUNG, WAI-PING Inventor name: KARLSSON, LARS Inventor name: HOFSTRA, CLAUDIA, L. Inventor name: DUNFORD, PAUL, J. Inventor name: DESAI, PRAGNYA, J. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20070305 |